The psychedelics market is not expected to follow the pattern of cannabis, with many businesses trying to take a top-down approach. This article argues that while many of these businesses are well-intended, a bottom-up approach may be more effective.
Developing drugs from illegal compounds is challenging for companies as it does not look fiduciarily responsible, and they are only interested in substances if they can make billions of dollars. The outlaw of everything in the 1970s is also contributing to the difficulty of developing these drugs.
The opiate market is a big industry that profits off the addiction and dependency of individuals who are struggling with drug abuse. Pharmacies and companies profit off of individuals who need an alternative to the pain caused by their lack of internal opiates, leading to a vicious cycle of addiction.
Psychedelic companies are facing challenges as they try to take a top down approach to their business, with many of them failing due to their business being not as easy as providing an addictive substance to people.